Rhabdomyolysis caused by the moderate CYP3A4 inhibitor fluconazole in a patient on stable atorvastatin therapy: a case report and literature review

被引：12

作者：

Hsiao, S. -H. ^{[1
]}

Chang, H. -J. ^{[1
]}

Hsieh, T. -H. ^{[2
]}

Kao, S. -M. ^{[1
]}

Yeh, P. -Y. ^{[1
]}

Wu, T. -J. ^{[3
,4
]}

机构：

[1] Natl Cheng Kung Univ Hosp, Dept Pharm, Tainan, Taiwan

[2] Natl Cheng Kung Univ, Dept Internal Med, Med Coll & Hosp, Tainan, Taiwan

[3] Natl Cheng Kung Univ Hosp, Dept Internal Med, Tainan, Taiwan

[4] Natl Cheng Kung Univ, Coll Med, Tainan, Taiwan

来源：

JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS | 2016年 / 41卷 / 05期

关键词：

atorvastatin; drug interaction; fluconazole; rhabdomyolysis; FUSIDIC ACID; SIMVASTATIN; STATIN; SAFETY; AMIODARONE;

D O I：

10.1111/jcpt.12425

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

What is known and objectiveRhabdomyolysis is a severe potential adverse drug reaction of statin therapy. We report a case of rhabdomyolysis due to drug-drug interaction (DDI) between atorvastatin and fluconazole and review the literature. Case summaryA 70-year-old woman received atorvastatin for hyperlipidaemia without any problem for 4 years. When intravenous fluconazole was added for treating a fungal infection, rhabdomyolysis developed 2 weeks later. Removal of atorvastatin led to the resolution of her rhabdomyolysis. What is new and conclusionOur case demonstrates that in some subjects even a moderate CYP3A4 inhibitor such as fluconazole may lead to rhabdomyolysis in subjects receiving a statin. Characteristics of reported cases of rhabdomyolysis associated with drug interaction between statins and fluconazole.

引用

页码：575 / 578

页数：4

共 50 条

[1] EFFECT OF A MODERATE CYP3A4 INHIBITOR, FLUCONAZOLE, ON THE PHARMACOKINETICS OF FESOTERODINE IN HEALTHY SUBJECTS
Malhorta, B.
Alvey, C.
Jumadilova, Z.
Li, X.
Gandelman, K.
EUROPEAN UROLOGY SUPPLEMENTS, 2010, 9 (02) : 113 - 114
[2] Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects
Malhotra, Bimal
Dickins, Maurice
Alvey, Christine
Jumadilova, Zhanna
Li, Xiaoxi
Duczynski, Gregory
Gandelman, Kuan
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 72 (02) : 263 - 269
[3] Atorvastatin interactionInteraction with concomitant fluconazole leading to rhabdomyolysis in an elderly patient: case report
Reactions Weekly, 2007, 1179 (1) : 9 - 9
[4] Levofloxacin-induced rhabdomyolysis in a patient on concurrent atorvastatin: Case report and literature review
Bouchard, Jeannette
De La Pena, Nicolas
Oleksiuk, Louise-Marie
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2019, 44 (06) : 966 - 969
[5] Atorvastatin interactionFirst report of an interaction with concomitant fluconazole leading to rhabdomyolysis in an elderly patient: case report
Reactions Weekly, 2005, 1047 (1) : 6 - 7
[6] Infection-Induced Rhabdomyolysis in an Elderly Patient on Stable Rosuvastatin Therapy: A Case Report and Review of the Literature
Guo, Daxin
Meng, Zhangmin
He, Fuqian
Liu, Gongxiang
Huang, Xiaoli
AMERICAN JOURNAL OF THERAPEUTICS, 2022, 29 (06) : E657 - E661
[7] Fluconazole but not the CYP3A4 inhibitor, itraconazole, increases zafirlukast plasma concentrations
Karonen, Tiina
Laitila, Jouko
Niemi, Mikko
Neuvonen, Pertti J.
Backman, Janne T.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 68 (05) : 681 - 688
[8] Fluconazole but not the CYP3A4 inhibitor, itraconazole, increases zafirlukast plasma concentrations
Tiina Karonen
Jouko Laitila
Mikko Niemi
Pertti J. Neuvonen
Janne T. Backman
European Journal of Clinical Pharmacology, 2012, 68 : 681 - 688
[9] Dihydroxybergamottin caproate as a potent and stable CYP3A4 inhibitor
Ohta, T
Nagahashi, M
Hosoi, S
Tsukamoto, S
BIOORGANIC & MEDICINAL CHEMISTRY, 2002, 10 (04) : 969 - 973
[10] EFFECT OF DILTIAZEM, A MODERATE CYP3A4 INHIBITOR, ON THE PHARMACOKINETIC PARAMETERS OF TAMSULOSIN
Lee, Y.
Byeon, J. Y.
Kim, Y. H.
Kim, S. H.
Lee, H. J.
Lee, Y. J.
CLINICAL THERAPEUTICS, 2015, 37 (08) : E61 - E62

← 1 2 3 4 5 →